Oppenheimer Questions $14.5B Penumbra Deal Valuation Despite Boston Scientific's (BSX) Mew Market Dominance [Yahoo! Finance]
Boston Scientific Corporation (BSX)
Last boston scientific corporation earnings: 4/29 06:30 am
Check Earnings Report
US:NYSE Investor Relations:
investors.bostonscientific.com
Company Research
Source: Yahoo! Finance
target on Boston Scientific to $100 from $125 with an Outperform rating. Oppenheimer is cautious on the financial optics of Boston Scientific's $14.5 billion acquisition of Penumbra. Although the deal creates a powerhouse in the thrombectomy and neurovascular markets, analysts are questioning the valuation. At $374 per share, the high purchase multiple may hinder the company's ability to generate a strong ROIC, leading the firm to question whether the timing was ideal for such a large-scale transaction. Penumbra's acquisition represents Boston Scientific's second-largest takeover in its history and marks its re-entry into the neurovascular market. The move is designed to broaden Boston Scientific's cardiovascular and neurovascular portfolios. Having divested its neurovascular business to Stryker over a decade ago, Boston Scientific CEO Mike Mahoney emphasized that the company sought a scaled platform and a strong pipeline to return to this attractive segment. Penumbra is expected
Show less
Read more
Impact Snapshot
Event Time:
BSX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BSX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BSX alerts
High impacting Boston Scientific Corporation news events
Weekly update
A roundup of the hottest topics
BSX
News
- Boston Scientific Expands Neuromodulation And Obesity Trials As Valuation Stays Rich [Yahoo! Finance]Yahoo! Finance
- Boston Scientific Stock: Analyst Estimates & Ratings [Yahoo! Finance]Yahoo! Finance
- Boston Scientific Corporation (BSX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Is Boston Scientific (BSX) Pricing In Too Much Optimism After Mixed Share Performance? [Yahoo! Finance]Yahoo! Finance
- Prospect Medical bankruptcy dispute puts CT hospitals at risk of supply disruptions, attorney says [Yahoo! Finance]Yahoo! Finance
BSX
Earnings
- 10/22/25 - Beat
BSX
Sec Filings
- 1/21/26 - Form 425
- 1/15/26 - Form 8-K
- 1/15/26 - Form 8-K
- BSX's page on the SEC website